Emerging Poly-Agonists for Obesity and Type 2 Diabetes

Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease

(2016) Brian Finan et al.   CELL

Unimolecular Polypharmacy for Treatment of Diabetes and Obesity

(2016) Matthias H. Tschöp et al.   Cell Metabolism

Glucagon therapeutics: Dawn of a new era for diabetes care

(2016) Jaime A. Davidson et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents

(2014) Brian Finan et al.   NATURE MEDICINE

Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action

(2013) Jonathan E. Campbell et al.   Cell Metabolism

Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans

(2013) B. Finan et al.   Science Translational Medicine

Targeted estrogen delivery reverses the metabolic syndrome

(2012) Brian Finan et al.   NATURE MEDICINE

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents

(2009) Jonathan W Day et al.   Nature Chemical Biology